Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study.
Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study.
复制标题
DOI：
10.1155/2018/5854710
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Yu RH
中科院分区：
文献类型：
--
作者：
Shi B;Zhang RR;Liang Y;Wang XH;Lang R;Yu RH
成人难治性特发性膜性肾病使用类固醇和其他免疫抑制剂耐药肾病综合征的治疗可能是一个巨大的挑战。我们评价了中药健脾祛石方作为一种有前景的治疗方案的疗效和安全性。我们分析了从2013年10月到2017年1月连续15例经活检证实的免疫抑制治疗失败的特发性膜性肾病患者。早晚各口服2次，疗程6个月。所有患者均获得至少1年的随访。主要终点包括完全缓解或部分缓解。次要终点包括治疗12个月后临床参数的变化和不良事件。12个月后完全缓解率为13.3%，部分缓解率为66.7%，有效率为80%。蛋白尿、血清白蛋白和胆固醇明显改善(分别为P<；0.001、P<；0.001和P<；0.05)。治疗1年后，尿蛋白从5.93±2.54 g/24 h降至1.99±1.17 g/24 h(P<；0.001)。观察期间未发生严重不良事件。JPQSF可能是激素和全身免疫抑制剂抵抗的膜性肾病综合征患者的替代治疗选择，具有良好的安全性。评估这种疗法的更大规模和更长时间的随访研究是有必要的。
The treatment of adult refractory idiopathic membranous nephropathy with steroid and other immunosuppressant-resistant nephrotic syndromes can be a significant challenge. We evaluated the efficacy and safety of the traditional Chinese medicine Jian Pi Qu Shi Formula (JPQSF) as a promising regimen. We analyzed 15 consecutive patients with biopsy-proven idiopathic membranous nephropathy who failed immunosuppressive therapy from October 2013 to January 2017. JPQSF was administered orally two times per day, respectively, in the morning and at night for 6 months. All patients had at least 1 year of follow-up. The primary endpoints included complete or partial remission. Secondary endpoints included change of clinical parameters and adverse events after 12 months of treatment. After 12 months, complete remission was achieved in 13.3% of patients and partial remission in 66.7%, yielding a response rate of 80%. Proteinuria, serum albumin, and cholesterol were improved significantly (P<0.001, P<0.001, and P<0.05, respectively). After 1 year of treatment, proteinuria (mean ± SD) decreased from 5.93 ± 2.54 g per 24 h to 1.99 ± 1.17 g per 24 h (P<0.001). No serious adverse events occurred during the observation. JPQSF may be an alternative therapeutic option for steroid and general immunosuppressant-resistant membranous nephrotic syndrome patients, with a favorable safety profile. Larger and longer follow-up studies evaluating this regimen are warranted.
登录
查看更多内容
秋葵治疗原发性肾小球疾病的疗效和安全性：一项前瞻性、多中心随机对照临床试验
影响因子：
13.2
作者：
Zhang, Li;Li, Ping;Chen, Xiangmei
通讯作者：
Chen, Xiangmei
影响因子：
--
作者：
Nowack, Rainer;Birck, Rainer
通讯作者：
Birck, Rainer
影响因子：
2.3
作者：
Saito, Takao;Iwano, Masayuki;Matsumoto, Koichi;Mitarai, Tetsuya;Yokoyama, Hitoshi;Yorioka, Noriaki;Nishi, Shinichi;Yoshimura, Ashio;Sato, Hiroshi;Ogahara, Satoru;Shuto, Hideki;Kataoka, Yasufumi;Ueda, Shiro;Koyama, Akio;Maruyama, Shoichi;Nangaku, Masaomi;Imai, Enyu;Matsuo, Seiichi;Tomino, Yasuhiko
通讯作者：
Tomino, Yasuhiko
影响因子：
4.6
作者：
Cheng, Xiao-Lan;Liu, Xin-Guang;Liu, E-Hu
通讯作者：
Liu, E-Hu
影响因子：
6.1
作者：
du Buf-Vereijken, PWG;Branten, AJW;Wetzels, JFM
通讯作者：
Wetzels, JFM